Richard Formica, MD
Professor of Medicine (Nephrology) and Professor of Surgery (Transplant)Cards
About
Research
Publications
2026
Conference Report—The Past, Current, and Future Challenges in Transplantation: A Festschrift in Honor of Professor Paul Anthony Keown
Gill J, Stiller C, Lan J, Jevnikar A, Halloran P, Rush D, Nickerson P, Cole E, Matas A, Formica R, Sawinski D, Blosser C, Mannon R, Keown P. Conference Report—The Past, Current, and Future Challenges in Transplantation: A Festschrift in Honor of Professor Paul Anthony Keown. Canadian Journal Of Kidney Health And Disease 2026, 13: 20543581261434082. PMID: 42063677, PMCID: PMC13125847, DOI: 10.1177/20543581261434082.Peer-Reviewed Original ResearchA Sliding Scale AdaptiVe Expedited (SAVE) Rescue Algorithm for Deceased Donor Kidney Transplantation
Mehrotra S, Barah M, Kilambi V, Formica R. A Sliding Scale AdaptiVe Expedited (SAVE) Rescue Algorithm for Deceased Donor Kidney Transplantation. American Journal Of Transplantation 2026 PMID: 41895700, DOI: 10.1016/j.ajt.2026.03.018.Peer-Reviewed Original ResearchPlacing Organ Allocation Out of Sequence in the Proper Context
Formica R. Placing Organ Allocation Out of Sequence in the Proper Context. The American Journal Of Bioethics 2026, 26: 76-79. PMID: 41533123, DOI: 10.1080/15265161.2025.2594438.Peer-Reviewed Original Research
2025
The role of eplet matching in solid organ transplantation
Stögner V, Pucciarelli D, Harkins L, Littleton A, Formica R, Pomahac B, Haykal S. The role of eplet matching in solid organ transplantation. Frontiers In Transplantation 2025, 4: 1710058. PMID: 41438158, PMCID: PMC12719434, DOI: 10.3389/frtra.2025.1710058.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHuman leukocyte antigenSolid organ transplantationEplet matchingOrgan transplantationLong-term graft outcomeHuman leukocyte antigen moleculesImmunological risk assessmentKidney transplant cohortAssociated with inDonor-recipient compatibilityEplet mismatchesImmunosuppression exposureGraft dysfunctionHLA matchingGraft outcomeTransplant cohortT cellsLeukocyte antigenHLA-DQLiver transplantationClinical outcomesRisk stratificationProspective studyAlloimmunization riskMolecular typingTailoring of Immunosuppression With Belatacept in De Novo and Conversion Settings and Risk Mitigation Strategies
Formica R, Larsen C, Rostaing L. Tailoring of Immunosuppression With Belatacept in De Novo and Conversion Settings and Risk Mitigation Strategies. Transplantation 2025, 110: e302-e323. PMID: 40898400, DOI: 10.1097/tp.0000000000005506.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsBelatacept-based regimenCNI-based immunosuppressionCalcineurin inhibitorsAR riskMaintenance immunosuppressionIncidence of de novo donor-specific antibodiesClinical trialsRisk of new-onset diabetesConversion to belataceptDonor-specific antibodiesRenal transplant recipientsNew-onset diabetesReal-world studyDe novo settingBelatacept treatmentBelatacept usePatient/graft survivalLong-term useAllograft injuryAcute rejectionTransplant recipientsRenal functionBelataceptPatient subgroupsPosttransplant treatmentThe kidneys’ effect on the survival of multi-organ transplant recipients
Formica R. The kidneys’ effect on the survival of multi-organ transplant recipients. The Journal Of Heart And Lung Transplantation 2025, 45: 225-226. PMID: 40835056, DOI: 10.1016/j.healun.2025.07.031.Commentaries, Editorials and LettersSkin Elasticity: A Potential Surrogate Marker for Facial Allograft Skin Fibrosis—A Case Series
Stögner V, Boroumand S, Vafa A, Huelsboemer L, Kauke‐Navarro M, Formica R, Leffell D, Haykal S, Pomahac B. Skin Elasticity: A Potential Surrogate Marker for Facial Allograft Skin Fibrosis—A Case Series. Clinical Transplantation 2025, 39: e70175. PMID: 40460163, DOI: 10.1111/ctr.70175.Peer-Reviewed Original ResearchConceptsPost-transplant yearVascularized Composite AllotransplantationRecipient/donor ageImmunosuppressive regimensSurrogate markerSmoking statusVascularized composite allotransplantation recipientsPotential surrogate markersBilateral upper armsFace transplant recipientsSkin elasticity measurementsAllograft fibrosisChronic rejectionGraft lossTransplant recipientsBilateral cheeksCase seriesDermal fibrosisSkin changesFacial allograftDegenerative skin changesGraft changesFacial skinNet elasticityRejection burdenEffects of Donor-Recipient Race Matching on Kidney Transplant Survival
Chisholm-Burns M, Spivey C, Formica R. Effects of Donor-Recipient Race Matching on Kidney Transplant Survival. Annals Of Transplantation 2025, 30: e947720. PMID: 40457621, PMCID: PMC12144921, DOI: 10.12659/aot.947720.Peer-Reviewed Original ResearchConceptsDonor-recipient race-matchingDonor-recipient pairsPatient survivalGraft survivalRace-matchedPrimary kidney transplant recipientsKidney transplant graft survivalAdult primary kidney transplant recipientsKidney transplant recipientsKidney transplant outcomesKidney transplant survivalTransplant graft survivalScarcity of donor organsEMBASE literature searchGrading of recommendations assessmentInvestigation of modifiable factorsPatient population characteristicsTransplant recipientsGraft failureTransplant outcomesTransplant survivalEvidence certaintyPatientsPublic health concernInclusion criteriaThe Economic Value of Volunteers Directing and Managing the US Organ Donation and Transplantation System
Levan M, Flower T, Massie A, Rudow D, Sidoti C, Formica R, Ratner L. The Economic Value of Volunteers Directing and Managing the US Organ Donation and Transplantation System. Transplantation 2025, 109: e184-e185. PMID: 39865535, DOI: 10.1097/tp.0000000000005293.Peer-Reviewed Original ResearchThe prognostic relevance of donor-specific antibodies in facial transplantation – A retrospective cohort study
Huelsboemer L, Hosseini H, Klimitz F, Diatta F, Boroumand S, O'Brien C, Parikh N, Stögner V, Formica R, Ko C, Azzi J, Draper E, Lian C, Murphy G, Pomahac B, Kauke-Navarro M. The prognostic relevance of donor-specific antibodies in facial transplantation – A retrospective cohort study. Journal Of Plastic Reconstructive & Aesthetic Surgery 2025, 103: 286-296. PMID: 40043533, DOI: 10.1016/j.bjps.2025.01.028.Peer-Reviewed Original ResearchDe novo donor-specific antibodiesDonor-specific antibodiesDonor-specific antibody positivityChronic rejectionC4d depositionGraft lossPrognostic relevanceRejection gradeGrades of acute cellular rejectionDonor-specific antibody statusOccurrence of chronic rejectionTime pointsFacial Vascularized Composite AllotransplantationAcute rejection gradeAcute cellular rejectionTissue typing laboratoriesAcute rejection eventsRetrospective cohort studyTransplant-related outcomesFace transplant patientsVascularized Composite AllotransplantationCellular rejectionTransplant patientsC4d levelsRetrospective analysis
Clinical Trials
Current Trials
Kidney Transplantation in Recipients and Donors with HIV: Long Term Follow up Study
IRB ID2000030204RoleSub InvestigatorPrimary Completion Date03/31/2031Recruiting ParticipantsGenderBothAge18+ yearsHOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients
IRB ID2000022391RoleSub InvestigatorPrimary Completion Date08/01/2021Recruiting ParticipantsGenderBothAge18+ years
Academic Achievements & Community Involvement
Clinical Care
Overview
Richard Formica, MD, is a nephrologist and the director of transplant medicine at Yale Medicine. He received his medical education at Boston University School of Medicine before arriving at Yale in 1997.
As the director for transplant medicine, Dr. Formica strives to make his program a medical home for transplant patients. These patients tend to have a complex variety of needs that may be difficult for other physicians to address. Since arriving here, Dr. Formica has expanded Yale Medicine’s transplant program to include support staff, such as dietitians and social workers. “We wanted to be the one place where transplant patients can have all of their primary needs met so they wouldn’t have to move around to different physicians,” Dr. Formica says.
Dr. Formica’s relationships with his patients often span many years—sometimes beginning before the transplantation. He sees this relationship as a whole rather than as individual clinic visits. “I tell them, ‘Instead of thinking of this as 32 clinic visits over the course of a year, think of it as one experience,’” he says.
As a physician, Dr. Formica aims to keep things casual with his patients. He encourages them to use his first name and learns as much as he can about them, including aspects of their lives unrelated to their disease such as their pets, jobs and hobbies. He has a keen interest in how the disease is affecting his patients: “When I was younger, it was the physiology that drew me to nephrology. Now, what interesting to me is how the patient responds to their disease,” he says.
In addition to treating patients, Dr. Formica is involved in public policy work related to kidney transplantation. He helped develop the kidney allocation system for the country that went into effect in 2014 and he’s also involved in clinical trials for drugs that treat hypertension. At the Yale School of Medicine, he is a professor of medicine (nephrology) and surgery (transplant).
Clinical Specialties
Fact Sheets
High Blood Pressure (Hypertension)
Learn More on Yale MedicineLiving Donor Organ Transplantation
Learn More on Yale MedicineLiver Transplant
Learn More on Yale MedicineKidney Transplant
Learn More on Yale Medicine
Yale Medicine News
News & Links
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.